103 related articles for article (PubMed ID: 29265185)
1. A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.
Ghione P; Cavallo F; Visco C; Chen Z; Castellino A; Tisi MC; Dogliotti I; Nicolosi M; Boccadoro M; Leonard JP; Vitolo U; Martin P
Br J Haematol; 2018 Dec; 183(5):828-831. PubMed ID: 29265185
[No Abstract] [Full Text] [Related]
2. R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory study.
Lacout C; Orvain C; Seegers V; De Vries M; Mercier M; Farhi J; Clavert A; Thepot S; Moles MP; Ifrah N; Hunault-Berger M; Tanguy-Schmidt A
Eur J Haematol; 2020 Aug; 105(2):223-230. PubMed ID: 32302426
[TBL] [Abstract][Full Text] [Related]
3. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.
Lisenko K; Cremer M; Schwarzbich MA; Kriegsmann M; Ho AD; Witzens-Harig M; Wuchter P
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1397-1402. PubMed ID: 27060439
[TBL] [Abstract][Full Text] [Related]
4. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma.
Hill H; Arnall J; Janes A; Hatley C; Swift K; Hargett C; Howell T; Griffin S; Larck C; Park S
J Oncol Pharm Pract; 2019 Dec; 25(8):2041-2044. PubMed ID: 30616469
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
9. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
11. Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.
Machover D; Delmas-Marsalet B; Misra SC; Ulusakarya A; Gumus Y; Frénoy N; Guettier C; Saffroy R; Innominato P; Almohamad W; Brahimi N; Haydar M; Goldschmidt E
Biomed Pharmacother; 2010 Feb; 64(2):83-7. PubMed ID: 20044233
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
13. ASCT in follicular lymphoma.
Brown JR; Freedman AS
Nat Rev Clin Oncol; 2009 Jul; 6(7):380-2. PubMed ID: 19561632
[No Abstract] [Full Text] [Related]
14. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
[TBL] [Abstract][Full Text] [Related]
15. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.
Mey UJ; Olivieri A; Orlopp KS; Rabe C; Strehl JW; Gorschlueter M; Hensel M; Flieger D; Glasmacher AG; Schmidt-Wolf IG
Leuk Lymphoma; 2006 Dec; 47(12):2558-66. PubMed ID: 17169800
[TBL] [Abstract][Full Text] [Related]
16. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
Ladetto M; Vallet S; Benedetti F; Vitolo U; Martelli M; Callea V; Patti C; Coser P; Perrotti A; Sorio M; Boccomini C; Pulsoni A; Stelitano C; Scimè R; Boccadoro M; Rosato R; De Marco F; Zanni M; Corradini P; Tarella C
Leukemia; 2006 Oct; 20(10):1840-7. PubMed ID: 16932351
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. R-DHAP: a good small step, but not the journey's end.
McLaughlin P; Vose JM
Leuk Lymphoma; 2008 Jun; 49(6):1019-21. PubMed ID: 18452108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
